CLDX
$30.90+0.87 (+2.90%)
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific ant...
Recent News
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness And Strong 1 Year Return
What Celldex Therapeutics (CLDX) investors are looking at now Celldex Therapeutics (CLDX) has drawn fresh attention after recent trading left the share price at US$28.54, prompting investors to weigh its clinical pipeline against current valuation and recent return profile. See our latest analysis for Celldex Therapeutics. The recent 1 day and 7 day share price declines contrast with a strong 30 day share price return of 24.09% and a 1 year total shareholder return of 43.06%. This suggests...
Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts
Celldex Therapeutics (NASDAQ:CLDX) executives highlighted recent clinical progress and upcoming catalysts during a discussion at the Leerink Partners Global Healthcare Conference, with a major focus on the company’s Phase III program in chronic spontaneous urticaria (CSU) for barzolvolimab. Executi
Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference
Executives from Celldex Therapeutics (NASDAQ:CLDX) outlined a busy year of clinical and development milestones at the TD Cowen Healthcare Conference, highlighting completed enrollments in two Phase 3 chronic spontaneous urticaria (CSU) trials, the launch of a Phase 3 study in chronic inducible urtic
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory
We came across a bullish thesis on Celldex Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on CLDX. Celldex Therapeutics, Inc.’s share was trading at $30.82 as of February 25th. Celldex Therapeutics Inc. (CLDX) is emerging as an attractive biotech pick for 2026, driven by its advancing immunology pipeline and promising clinical […]